The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,769.00
Bid: 1,769.00
Ask: 1,769.50
Change: 8.00 (0.45%)
Spread: 0.50 (0.028%)
Open: 1,770.00
High: 1,772.50
Low: 1,766.00
Prev. Close: 1,761.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: Shell Overtakes BP Amid Mixed London Trading

Wed, 30th Apr 2014 09:47

LONDON (Alliance News) - UK stocks trade mixed Wednesday, as investors await a raft of releases from the US and after the preliminary reading of eurozone consumer price inflation accelerated from a more than four-year low, but still missed forecasts.

By mid-morning, the FTSE 100 is marginally higher at 6,773.55, the FTSE 250 is down 0.4% at 15,838.4, and the AIM All-Share is up 0.6% at 820.65.

It is a similar story in Europe, where the DAX 30 in Frankfurt is up 0.1%, while the CAC 40 in Paris is down 0.2%.

In data just released, consumer price inflation in the euro area increased to 0.7% in April from 0.5% in March. Although this meant CPI edged up from its 2009 lows, it fell short of the 0.8% that economists had been expecting.

"The ship is starting to sink and time is running out for the European Central Bank to divert a 1990s Japanese-style bout of deflation," says Dennis de Jong, managing director at UFXMarkets. "Inflation simply isn?t rising quick enough and stimulus is required, be it through the introduction of quantitative easing or negative interest rates. (ECB President) Mario Draghi has said that he is prepared to take emergency measures, but now is the time for action rather than words.

The euro dropped to a three-week low against the dollar in the aftermath of the data, before almost immediately regaining its losses, and then some. The single currency currently trades at USD1.3827, while the pound trades at USD1.6817.

Within UK equities, oil and gas producers are big risers, with the FTSE 350 sector up 2.3%.

Royal Dutch Shell is the biggest riser in the FTSE 100, up 4.4%. The oil and gas giant, which has now overtaken BP as the second largest company in the FTSE 100 by market capitalisation after HSBC Holdings, said its earnings almost halved in the first quarter of the year, as it wrote down some of the value of its refineries in Europe and Asia due to declining refining margins and as its production fell.

However, like its peer BP on Tuesday, Shell said it would pay a higher dividend for the quarter as it returns some of the funds from its asset sale programme to its shareholders.

Tullow Oil is another big blue-chip riser, up 3.2%. The company has pushed ahead with the sale of its UK gas assets in the southern North Sea, selling stakes in two assets to AIM-listed Faroe Petroleum for USD75.6 million plus a royalty on developments at one of the assets.

In the FTSE 250, Heritage Oil is the leading gainer. The firm's shares are up 22% after it said it had recommended shareholders accept a GBP924 million takeover offer from Al Mirqab Capital, an investment vehicle controlled by the royal family of Qatar.

Away from the oil and gas producers, Rolls-Royce is big winner Wednesday, up 2.6%. Shares in the company jumped after it said late on Tuesday that it is in talks with Germany's Siemens AG about a possible sale of its energy gas turbine and compressor business.

At the other end of the spectrum, Standard Life is one of the biggest fallers in the FTSE 100, currently down 1.7%. The Edinburgh-based long-term savings and investments provider said its assets under administration increased 1.5% in the first quarter driven by net inflows, but said recent changes to annuity regulations in the UK resulted in a reduction in UK annuity sales of around 50%.

However, the five heaviest fallers in the index are all companies that have gone ex-dividend Wednesday, meaning new buyers no longer qualify for the latest dividend payout from each of the companies. Tesco is down 3.5%, Admiral Group is down 3.4%, Reed Elsevier is down 3.1%, William Hill is down 2.8%, and Weir Group is down 1.9%

Still to come in the corporate calendar Wednesday, GlaxoSmithKline is due to release its first quarter results at 1100 GMT. Ahead of the release, the pharmaceutical giant's shares are down 1.3%.

In the data calendar, Italian produce price index numbers are released at 1000 GMT.

In the US, the Mortgage Bankers Association releases its MBA mortgages applications data at 1100 GMT. Shortly after, the ADP employment change figure for April, released at 1215 GMT, is expected to report that the world's largest economy added 210,000 new jobs in April, up from the 191,000 added in March. The preliminary reading of US first quarter GDP is published at 1230 GMT. Expectations are for US GDP to have decelerated to annualised reading of 1.2%, down from 2.6%. The Chicago purchasing managers' index is released at 1345 GMT.

Later in the day, the US Federal Open Market Committee publishes its latest interest rate and monetary policy decisions at 1800 GMT.

By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.